Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL
Covered in this story
Analyst targets on Nurix Therapeutics Inc
- Morgan Stanley: $23.4 → $38 by Jul 2027 · Overweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $NRIX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Nurix Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.